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Abstract
Background: The increasing incidence of cancer and the search for more effective therapies with minimal
collateral effects have prompted studies to find alternative new treatments. Among these, photodynamic therapy
(PDT) has been proposed as a very promising new modality in cancer treatment with the lowest rates of side
effects, revealing itself to be particularly successful when the photosensitizer is associated with nanoscaled carriers.
This study aimed to design and develop a new formulation based on albumin nanospheres containing
zinc-phthalocyanine tetrasulfonate (ZnPcS4-AN) for use in the PDT protocol and to investigate its antitumor activity
in Swiss albino mice using the Ehrlich solid tumor as an experimental model for breast cancer.
Methods: Ehrlich tumor’s volume, histopathology and morphometry were used to assess the efficacy of
intratumoral injection of ZnPcS4-AN in containing tumor aggressiveness and promoting its regression, while the
toxicity of possible treatments was assessed by animal weight, morphological analysis of the liver and kidneys,
hemogram, and serum levels of total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatase, creatinine and urea. In
order to evaluate the efficacy of PDT, groups of animals treated with intratumoral injection of doxorubicin (Dox)
were also investigated.
Results: Intratumoral injection of ZnPcS4-AN was found to be efficient in mediating PDT to refrain tumor
aggressiveness and to induce its regression. Although tumor volume reduction was not significant, PDT induced a
remarkable increase in the necrosis area seen in the tumor’s central region, as in other experimental groups,
including tumor and Dox treated groups, but also in the tumor’s peripheral region. Further, PDT showed minimal
adverse effects. Indeed, the use of ZnPcS4-AN in mediating PDT revealed anti-neoplastic activity similar to that
obtained while using intratumoral Dox therapy.
Conclusions: PDT mediated by the new formulation ZnPcS4-AN enhanced the inhibition of tumor growth while
producing practically no adverse effects and thus emerges as a very promising nanotechnology-based strategy for
solid cancer treatment.
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Background
The increasing incidence of cancer and the search for
the development of more effective therapies with minimal
side effects have prompted studies to find alternative new
treatments. Among new therapies, photodynamic therapy
(PDT) appears as a promising modality in cancer treat-
ment with the lowest rates of side effects. Since the 1990s
PDT has been investigated in basic research and showed
to be more effective when nanostructured materials are
used as the drug delivery system (DDS) for the active
compounds [1-7]. Nowadays, interest in using PDT is in-
creasing as a result of its recognition by the FDA (U.S.
Food and Drug Administration) and other world agencies
as an effective therapy for the treatment of several dis-
eases, including cancer [8]. PDT is currently being used in
the clinical phase for treatment of several types of tumors
[9,10] around the world [11-14]. However, this therapy
is particularly effective in the treatment of easily access-
ible lesions, such as non-melanoma skin cancers and le-
sions with well-defined borders [2], although it has been
used outside oncology applications, including ophthal-
mology, dermatology, cardiology, virus inactivation, and
blood purification [1].
PDT consists in the systemic or topical application of
a photosensitizer that, after a specific time interval for
distribution, displays preferential accumulation in the neo-
plastic tissue. Subsequently, photosensitizer molecules
are irradiated with laser light of a particular wavelength
to induce photochemical and photophysical phenomena,
marked by the occurrence of energy transfer to the nearby
oxygen, generating reactive oxygen species as singlet oxy-
gen, hydroxyl radical, and superoxide anions. As a result
of PDT-induced oxidative stress, cellular organelles and
membranes become damaged, a process recognized as
tumor photodamage. Singlet oxygen causes microvascular
acute injury and blood vessel blockage in tumor and in-
duces apoptosis of tumor cells, achieving the purpose of
local treatment [4,15-17].
Successful pre-clinical and clinical studies resulted in
the first officially approved photosensitizing drug for
use in PDT of selected tumors, known as Photofrin®,
a semi-purified hematoporphyrin derivative [1-3]. Fol-
lowing Photofrin® other first-generation photosensitizers
have also been approved [1,2]. In addition, some second-
generation photosensitizers are now being submitted to
clinical testing in research centers in various countries,
including Brazil [5,14,17]. The second generation com-
pounds have been designed to improve the uptake of se-
lective tumor cells while taking advantage of the increased
depth penetration of light with a longer wavelength than
that used to activate Photofrin®. Second-generation pho-
tosensitizers are generally pure, can be activated by light
in the wavelength range of 630–800 nm, and all share a
lower incidence of prolonged cutaneous photosensitivity
compared to Photofrin® [1]. Among them, phthalocya-
nines absorb light between 630 and 700 nm and provide
maximum tissue penetration, thus presenting properties
for tumor localization and high efficiency as a photosensi-
tizing agent [18,19]. The most favorable photophysical
properties of phthalocyanines to be used in PDT are
dependent upon the core metal ion which comprises their
molecular structure. They can be attached to metals such
as zinc or aluminum, forming zinc-phthalocyanine or
chloride-aluminum-phthalocyanine complexes [20,21].
Most photosensitizers which are used clinically or in
preclinical development are hydrophobic and strongly
aggregate in aqueous media, including phthalocyanines.
Aggregation significantly reduces the photosensitizing effi-
cacy as only monomeric species are appreciably photoactive
[15,21]. The aggregation tendency may be minimized by
using a nanostructured photosensitive molecular structure
and also through the non-covalent binding of photosensi-
tizers to a carrier molecule, such as albumin [21]. While
photosensitizers can reach the lesion more easily, and thus
selectively accumulate in tumor tissues, molecular associ-
ation with albumin may be performed in physiological solu-
tions, thus conferring biocompatible characteristics to the
formulation [20]. To further enhance the selective release
and accumulation of photosensitizers at the targeted tissue,
various carriers and drug delivery systems have been inves-
tigated [1,5,14,21-25].
Aiming to potentialize the outcomes while using nano-
structured drug delivery systems carrying phthalocya-
nines as photosensitizers, in the present study we report
on the fabrication of a new albumin-based nanosphere
containing zinc-phthalocyanine tetrasulfonate (ZnPcS4-AN)
and further investigate its antitumor activity while medi-
ating photodynamic therapy. To conveniently evaluate the
new ZnPcS4-AN for PDT efficacy, groups of animals
treated with intratumoral injection of doxorubicin (Dox)
were also investigated.
Results
ZnPcS4-AN characterization
Scanning electron micrographs of the ZnPcS4-AN sample
reveal the spherical shape (Figure 1) with smooth surface,
as expected for this kind of system [26,27], whereas the
analysis of the nanosphere size reveals that the employed
preparation method produced nanospheres with average
diameter of 320 nm.
Fluorescence spectra were obtained by exciting the
samples (suspended in phosphate buffer) at 612 nm while
the emission was recorded in the range of 640–780 nm
(Figure 2). Bandwidths were fixed at 5 nm for excitation
and emission.
As observed in Figure 2 encapsulation of the ZnPcS4
within the BSA-based nanosphere leads to a small blue shift
of the peak emission in comparison to the characteristic
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peak emission of the free photosensitizer at 690 nm, which
corresponds to the maximum fluorescence emission wave-
length of ZnPcS4.
The obtained results indicate that the drug delivery sys-
tem did not affect the photophysical and phobiological
properties of the ZnPcS4 in the ground and excitated
states, responsible for the complex photophysical pathway
that leads to the biological response by PDT treatment
[26,27]. In other words, the ZnPcS4 maintains its activity
with the advantage of being encapsulated in a biocompat-
ible system, in this case the BSA-based nanospheres. The
final analysis developed in the ZnPcS4-AN sample are
based on zeta potential and particle size analyses.
The zeta potential data and the hydrodynamic particle
size evaluation support the observed physico-chemical
stability and reveal the size homogeneity of the as-pre
pared submicron-sized polymeric particles (see Table 1).
No appreciable variation on the average values of zeta po-
tential and hydrodynamic particle size characteristics were
observed up to 30 days of samples evaluations. As shown
in Table 1 the ZnPcS4-AN sample presented negative zeta
potential values. This picture is consistent with the high
colloidal stability of ZnPcS4-AN sample upon dispersion
and the high negative value of the zeta potential [28].
Tumor dimensions, histology, and percentage of necrosis
Photodynamic therapy performed with the albumin-based
nanospheres containing zinc-phthalocyanine tetrasulfonate
(ZnPcS4-AN) (PDT group) showed no significant tumor-
volume reduction (Figure 3A) when compared to non-
Figure 1 Scanning electron micrograph of sample ZnPcS4-AN. The photomicrography shows the spherical shape of the nanospheres with
smooth surface.
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Figure 2 Normalized fluorescence emission spectrum of ZnPcS4 (−) and ZnPcS4-AN (−) in PBS. ZnPcS4−AN presents a small blue shift of
the peak emission in comparison to the characteristic peak emission of ZnPcS4at 690 nm.
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treated tumor (CT group), whereas treatments with doxo-
rubicin (Dox group) and doxorubicin associated with laser
exposure (Dox/LS group) caused a significant reduction in
tumor-volume. However, morphometric evaluation showed
the highest level of necrosis after photodynamic therapy
using ZnPcS4-AN (PDT group, 66 ± 5% necrosis). Sig-
nificant necrosis was also observed with laser treatment
(LS group, 26 ± 3% necrosis), and all doxorubicin groups:
Dox (65 ± 4% necrosis), ZnPc/Dox (60 ± 4% necrosis),
Dox/LS (56 ± 2% necrosis) and Dox/PDT (59 ± 6% necro-
sis) (Figure 3B).
Histological sections from control Ehrlich tumor (CT
group) showed a typical pattern consisting of a peripheral
area of viable tumor layers surrounding a central area of
necrotic tissue. Viable tumor tissues showed the presence
of intact nucleus, cytoplasm limits and isolated mitotic
figures, as identified by the hematoxylin staining. In con-
trast, necrotic tissues were characterized by an amorphous
eosinophilic mass without cytoplasmic membrane integ-
rity and absence of cell nucleus. Necrotic areas were also
highly infiltrated by defense cells, especially neutrophils
(data not showed), which were also identified in all experi-
mental groups, especially in the central areas. Differences
in variations of necrotic area distribution inside tumors
were identified among the PDT group and other experi-
mental groups, including the control tumors (CT, ZnPc,
and LS) and the tumor groups treated with doxorubicin
(Dox, ZnPc/Dox, Dox/LS, and Dox/PDT). We found that
photodynamic therapy induced the presence of necrotic
tissue in both central and peripheral areas of tumor sec-
tions (Figure 4).
Histology of liver and kidneys
Macroscopically, all animals (including the PDT group)
presented kidneys with normal appearance characterized
by pink-red coloration and firm consistency. By light mi-
croscopy, only two animals treated with Dox and subjected
to PDT (Dox/PDT group) presented some organ alteration,
showing mild mononuclear inflammatory infiltration with
predominantly focal distribution (data not showed). Ani-
mals from all groups also showed liver of normal appear-
ance in macroscopic terms, with reddish brown coloration
and firm consistency. By light microscopy, only the liver of
the Dox group presented some alteration, with few inflam-
matory cells inside the vessel near the vascular wall and he-
patocytes with cytoplasmic vacuolation (Figure 5).
Hematology
Erythrogram
A significant reduction in red blood cells (RBC) and
hematocrit (HCT) was observed after the PDT and also
in almost all treatments compared to the negative con-
trol, except in the Dox and Dox/PDT groups for RBC
and Dox group for HCT. However, except for the ZnPc
group, RBC values remained inside the reference values
for mice (7.3-10.5 × 106/μL) [29]. It is noteworthy that
this was the only change in erythrogram parameters in-
duced by PDT, although the components of PDT (ZnPc
and LS) may cause some other alterations. The ZnPc
group, as well as the Dox/LS group, also presented sig-
nificantly decreased hemoglobin (HGB) values. Mean
corpuscular hemoglobin (MCH) fell significantly for the
CT, LS and ZnPc groups, while the mean corpuscular
hemoglobin concentration (MCHC) fell in CT, LS, Dox,
ZnPc/Dox, and Dox/PDT treatment groups. No signifi-
cant differences with respect to the negative control
were observed for mean corpuscular volume (MCV) or
red cell distribution width (RDW) (Table 2).
Table 1 Characterization of ZnPcS4-AN sample
Sample Hydrodynamic
diameter (nm)
Size dispersion
(μm)
Zeta potential
(mV)
ZnPcS4-AN 238.0 ± 0.3 11.00 ± 0.04 −38.6 ± 0.4
Figure 3 Tumor characteristics after photodynamic therapy and doxorubicin treatment. Sections refer to: (A) tumor volume and (B)
percentage of necrosis. Bar graphs were expressed as SEM (standard error of mean). Asterisks indicate significant (*p < 0.05) and highly significant
(**p < 0.01) differences detected by the Mann Whitney U test, with a = significant compared to CT group; b = significant compared to ZnPc
group; c = significant compared to LS group. For groups’ nomenclature see Table 5.
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Leukogram
Control tumor and all treatment groups, including the
PDT group, presented a significant decrease in lymphocytes
with a concomitant increase in neutrophils +monocytes
compared to healthy animals (negative control), whereas no
significant change was observed for eosinophils (Figure 6).
Plateletgram
With respect to the negative control and except for Dox
and Dox/PDT, significantly increased platelets were ob-
served for control tumor, PDT group and almost all
other treatment groups. The PDT group also showed an-
other alteration: a significant increase in the platelet
large cell ratio (P-LCR), also observed for ZnPc and LS.
Alterations in other plateletgram parameters were not
observed after PDT. Mean platelet volume (MPV) sig-
nificantly increased only for the ZnPc group, whereas
platelet distribution width (PDW) increased for ZnPc,
Dox/LS, and Dox/PDT groups. However, no conclusive
result was obtained for the ZnPc/Dox group, as the plate-
letgram could only be evaluated in one animal (Table 3).
Biochemical analyses
Although significant differences (with respect to the
negative control) were observed for the direct and indir-
ect bilirubin, aspartate aminotransferase (AST), alkaline
phosphatase, creatinine and urea (Table 4) in several treat-
ment groups, including the non-treated tumor control
(CT group), photodynamic therapy (PDT group) caused
significant alterations only in the indirect bilirubin and al-
kaline phosphatase evaluations. It is noteworthy that al-
though the PDT components (ZnPc and LS groups)
presented significant alterations for direct bilirubin and
urea when compared to the negative control group (NC),
similar alterations were not observed in the PDT group.
The biochemical values observed after doxorubicin treat-
ment (Dox group) were not significantly different from the
PDT group data. However, when PDT and Dox are com-
bined (Dox/PDT group), direct bilirubin is higher than in
the PDT group, although not differing from the NC group.
Discussion
Cancer research has been conducted in order to find an
appropriate treatment for each type of neoplasm. PDT is
considered an effective method for early treatment of can-
cer and a palliative treatment of advanced cancer [30].
Using a combination of nontoxic photosensitizing chem-
ical and visible light to destroy the tumor through the gen-
eration of reactive oxygen species [30], PDT presents
advantages over chemotherapy, such as lower toxicity and
higher safety in the treatment of malignant lesions [31].
However, there are limitations on the use of PDT, as the
efficacy of the treatment depends on the light penetration
into the target tissue and also on the photophysical and
photochemical characteristics of the chosen photosensitiz-
ing agent [32].
Figure 4 Ehrlich tumor histopathology after photodynamic therapy and doxorubicin treatment. Sections refer to: (A) control tumor, (B)
albumin-ZnPc treated tumors, and (C) doxorubicin treated tumor presenting central area of tumor necrosis (N) and viable cells in the tumor
periphery (V). Section (D) represents the tumor treated with PDT, showing the necrotic tissue in the central and peripheral areas of the tumor.
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Table 2 Effects of ZnPcS4-AN-based PDT and/or Dox treatments on erythrogram parameters of healthy and Ehrlich
solid tumor-bearing mice
Group Treatment RBC (x 106/μL) HGB (g/dL) HCT (%) MCV (fL) MCH (pg) MCHC (g/dL) RDW (%)
1 NC 8.8 ± 0.1 12.8 ± 0.1 31.5 ± 0.3 35.8 ± 0.1 14.5 ± 0.1 40.5 ± 0.2 13.01 ± 0.09
2 CT 8.6 ± 0.2 12.0 ± 0.2 30.7 ± 0.5 35.7 ± 0.3 13.9 ± 0.1**a 38.9 ± 0.2**a 13.6 ± 0.3
3 ZnPc 6.6 ± 0.7**a.*b 9.2 ± 0.9**a.*b 23.3 ± 2.5**a. *b 35.6 ± 0.4 14.2 ± 0.3 39.9 ± 0.5 14.1 ± 0.7
4 LS 8.5 ± 0.1*a.c 11.9 ± 0.2**c 30.5 ± 0.5*a.**c 36.0 ± 0.1 14.08 ± 0.08**a 39.1 ± 0.2**a 13.1 ± 0.2
5 PDT 8.1 ± 0.2**a.*b.d 11.4 ± 0.3**c 29.0 ± 0.6**a.*b 35.7 ± 0.2 14.0 ± 0.1 39.2 ± 0.2 14.0 ± 0.3
6 Dox 7.8 ± 0.3 11.1 ± 0.3 30 ± 1 38 ± 2 14.1 ± 0.3 38 ± 1**a 13.5 ± 0.4
7 ZnPc/Dox 8.0 ± 0.4*a 10.9 ± 0.5 28 ± 1**a 35.25 ± 0.05 13.60 ± 0.00*a.d 38.50 ± 0.00*a.c.d 13.8 ± 0.4
8 Dox/LS 7.6 ± 0.4**a.*b.d 10.9 ± 0.5*a 27 ± 1*a.d.**b 35.8 ± 0.7 14.3 ± 0.1*b 39.9 ± 0.5 13.5 ± 0.6
9 Dox/PDT 8.3 ± 0.2.*c.h 11.8 ± 0.2**c 30.1 ± 0.6*a.**c 36.2 ± 0.3 14.18 ± 0.12*g 39.2 ± 0.1**a.*g 14.2 ± 0.3
P-values 0.000 0.000 0.000 0.195 0.018 0.000 0.033
Data were expressed as mean ± SEM (standard error of mean). RBC = Red Blood Cells; HGB = Hemoglobin; HCT = Hematocrit; MCV =Mean Corpuscular Volume;
MCH =Mean Corpuscular Hemoglobin; MCHC =Mean Corpuscular Hemoglobin Concentration; RDW = Red cell Distribution Width (represents an indication of the
amount of variation − anisocytosis − in cell size); g/dL = grams per deciliter; fL = fentoliters; pg = picograms. P-values of HGB, MCV and RDW were generated by
ANOVA, while other p-values were generated by Kruskal-Wallis test. Lower-case letters indicate significant diferences in 2-by-2 comparisons detected by Bonferroni
(HGB, MCV and RDW) or Mann–Whitney (other variables) tests, with a = significant compared to group 1; b = significant compared to group 2; c = significant
compared to group 3; d = significant compared to group 4; e = significant compared to group 5; f = significant compared to group 6; g = significant compared to
group 7; h = significant compared to group 8. Asterisks indicate significant differences (*p < 0.05) or highly significant (**p < 0.01). For details of experimental
groups see Table 5.
Figure 5 Kidney and liver photomicrographs after photodynamic therapy and doxorubicin treatment. (A), (B), (C) and (D): Negative
control (NC); (E) and (F): Doxorubicin treated group (Dox). Sections: (A) Cortical (CR) and medular (MR) regions of the kidney. Bar = 250 μm; (B)
renal corpuscle in the center. In the detail (rectangle), the macula densa. Bar = 50 μm. (C) General aspect of hepatic tissue. Bar = 250 μm. (D) CV:
centrolobular vein, binucleate hepatocyte (circle) and sinusoids (square). (E) Inflammatory infiltrate next to the vein observed in a Dox treated
animal. (F) Degenerative process of the liver. For (D), (E) and (F), Bar = 50 μm.
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Surface decoration of nanoparticles represents a cru-
cial factor in biomedical applications, such as when col-
loidal stability is needed for longer periods of time, or
for preventing particle agglomeration and premature pre-
cipitation. The pharmacokinetic characteristics of zinc
phthalocyanine (ZnPc), such as long residence in the acti-
vated state and intense absorption in the visible red band,
make this molecule a very promising second-generation
photosensitizer for use in PDT [33]. However, to avoid its
agglomeration in aqueous media, particularly the tendency
to aggregate in physiological solution, the use of a non-
covalent binding of ZnPc to a carrier template is highly
recommended [1,20-22]. Since cancer cells overexpress
the albumin receptor to favor the capture of the nutrient
Figure 6 Percentage of differential leukocyte counts after PDT and DOX treatments. Negative control (NC) received filtered water and no
tumor implantation took place. In the control tumor (CT), tumor was implanted and no treatment was performed. Bar graphs were expressed as
SEM (standard error of mean). Asterisks indicate highly significant differences (**p < 0.01) detected by the Bonferroni test, with a = significant
compared to NC group. For groups’ nomenclature see Table 5.
Table 3 Effects of ZnPcS4-AN-based PDT and/or Dox treatments on plateletgram parameters of healthy and Ehrlich
solid tumor-bearing mice
G Treatment PLT (× 103/μL) MPV (fl) P-LCR (%) PDW (fl)
1 NC 1172 ± 50 6.31 ± 0.06 6.4 ± 0.3 6.77 ± 0.04
2 CT 1496 ± 50**a 6.5 ± 0.1 8.1 ± 0.9 6.80 ± 0.07
3 ZnPc 1503 ± 300*a 7.0 ± 0.1**a 9.4 ± 0.5**a 7.3 ± 0.2*a
4 LS 1366 ± 70*a 6.54 ± 0.07 7.8 ± 0.5*a 6.86 ± 0.07
5 PDT 1528 ± 100**a 6.7 ± 0.1 8.4 ± 0.6*a 6.9 ± 0.1
6 Dox 1312 ± 200 6.6 ± 0.3 8 ± 1 6.9 ± 0.3
7 ZnPc/Dox(1) 1219 7.10 12.70 6.90
8 Dox/LS 1808 ± 90**a.*b.d 6.3 ± 0.2*c 7 ± 2 6.53 ± 0.03**a.*b.c.d
9 Dox/PDT 1390 ± 80*h 6.3 ± 0.1**c 6 ± 1**c 6.6 ± 0.1*a.c
P-values 0.005 0.000 0.026 0.035
Data were expressed as mean ± SEM (standard error of mean). G = Group; PLT = Platelet Count; MPV =Mean Platelet Volume; P-LCR = Platelet Large Cell Ratio;
PDW = Platelet Distribution Width; fl = fentoliters. P-values of MPV were generated by ANOVA, while other p-values were generated by Kruskal-Wallis test.
Lower-case letters indicate significant diferences in 2-by-2 comparations detected by Bonferroni (MPV) or Mann–Whitney test (other variables), with a = significant
compared to group 1; b = significant compared to group 2; c = significant compared to group 3; d = significant compared to group 4; h= significant compared to
group 8. Asterisks indicate significant differences (*p < 0.05) or highly significant (**p < 0.01).
(1)Corresponds to the count of only one animal (the other samples coagulated). It was not used in statistical analyses of plateletgram. For details of experimental
groups see Table 5.
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Table 4 Effects of ZnPcS4-AN-based PDT and/or Dox treatments on biochemical parameters of healthy and Ehrlich solid tumor-bearing mice
G T Total bilirubin
(mg/dL)
Direct bilirubin
(mg/dL)
Indirect bilirubin
(mg/dL)
AST (U/L) ALT (U/L) GGT (U/L) Alkaline
phosphatase (U/L)
Creatinine (mg/dL) Urea (mg/dL)
1 NC 0.10 ± 0.00 0.04 ± 0.00 0.06 ± 0.00 71 ± 4 35 ± 2 1.88 ± 0.09 115 ± 9 0.20 ± 0.03 59 ± 2
2 CT 0.10 ± 0.00 0.03 ± 0.00**a 0.08 ± 0.00**a 186 ± 30**a 36 ± 3 1.8 ± 0.3 68 ± 8**a 0.20 ± 0.08 57 ± 5
3 ZnPc 0.10 ± 0.00 0.02 ± 0.00**a 0.08 ± 0.00**a 236 ± 30**a 44 ± 3 2.00 ± 0.00 41 ± 6**a. *b 0.16 ± 0.02 46 ± 3**a
4 LS 0.10 ± 0.00 0.02 ± 0.00**a 0.08 ± 0.00**a 96 ± 20*c 33 ± 6 2.3 ± 0.3 42 ± 9**a. *b 0.44 ± 0.09*a.b.c 39 ± 9*a
5 PDT 0.10 ± 0.00 0.02 ± 0.00 0.08 ± 0.00**a 162 ± 80 30 ± 9 1.9 ± 0.1 44 ± 7**a 0.29 ± 0.05 44 ± 8
6 Dox 0.10 ± 0.00 0.03 ± 0.00*d 0.07 ± 0.00*d 174 ± 20**a 37 ± 4 1.5 ± 0.3*c.d 53 ± 10 0.25 ± 0.06 55 ± 3
7 ZnPc/Dox 0.10 ± 0.00 0.02 ± 0.00**a 0.08 ± 0.00**a 160 ± 10**a 27 ± 2 1.8 ± 0.3 47 ± 10**a 0.25 ± 0.03*c 50 ± 3
8 Dox/LS 0.10 ± 0.00 0.03 ± 0.00*d 0.07 ± 0.00*d 162 ± 20**a.*d 35 ± 4 2.00 ± 0.00 88 ± 20*c.d 0.18 ± 0.03 56 ± 5
9 Dox/PDT 0.3 ± 0.2 0.04 ± 0.01*d.e 0.2 ± 0.2 106 ± 20*a.b.f.**c 25 ± 4 3 ± 1 42 ± 6 0.20 ± 0.02 39 ± 6
P-values 0.393 0.000 0.001 0.000 0.247 0.519 0.000 0.067 0.025
Data were expressed as mean ± SEM (standard error of mean). G = Group; T = Treatment; AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase; GGT = Gamma-Glutamyl Transferase; mg/dL =miligrams per
deciliters; ULl = Units per liter. P-values of ALT were generated by ANOVA, while other values were generated by Kruskal-Wallis test. Lower-case letters indicate significant diferences in 2-by-2 comparations detected by
Bonferroni (ALT) or Mann–Whitney (other variables) tests, with a = significant compared to group 1; b = significant compared to group 2; c = significant compared to group 3; d = significant compared to group 4; e =
significant compared to group 5; f = significant compared to group 6. Asterisks indicate significant differences (*p < 0.05) or highly significant (**p < 0.01 or p < 0.001). For details of experimental groups see Table 5.
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albumin [21], the use of albumin polymers as carriers of
ZnPc may offer the advantage of increasing absorption of
the photosensitizer by tumor cells, in addition to prevent-
ing degradation of photosensitizer before it achieves its
biological effect [23]. Our findings demonstrated that al-
bumin nanospheres containing zinc-phthalocyanine tetra-
sulfonate were indeed efficient in mediating PDT for
tumor remission, in very good agreement with the litera-
ture [34]. Ehrlich tumor is a very aggressive tumor that
spontaneously presents a central necrosis process [35,36].
Due to its aggressive pattern, this tumor type can be main-
tained in ascitic forms as a source of tumor cells for sub-
sequent subcutaneous tissue injections to produce solid
tumors. Although histological sections of Erhlich tumor in
the present study had a typical pattern that consisted of a
peripheral area of viable tumor layers surrounding a cen-
tral area of necrotic tissue [37], necrosis areas were found
in both the central area and in the peripheral regions of
the tumor in the group treated with PDT, where the pres-
ence of inflammatory infiltrates and hemorrhages in blood
vessels was also observed. Similar results were also re-
ported by Longo et al. [25]. Since there was a significant
increase in the percentage of necrotic area in the PDT
group, the observed infiltration of inflammatory cells after
PDT procedure was possibly responsible for the slight re-
duction in tumor volume when compared to the control
tumor. Moreover, tumor volume of animals treated with
PDT was not statistically different from treatment with
Dox alone. These results, combined with tumor morphom-
etry findings, suggest that the efficacy of PDT in reducing
the tumor was similar to the outcomes obtained while
using Dox therapy.
Doxorubicin is a cytotoxic anthracycline antibiotic widely
used in clinical practice for treatment of hematological
malignancies and solid tumors, including breast cancer
[38-40]. The anticancer effects of doxorubicin are mainly
due to its ability to intercalate within DNA, to inhibit
topoisomerase II and to modify helicases dissociating du-
plex DNA into single stranded DNA, thus preventing
DNA replication. Further, it also generates reactive oxygen
species (ROS) that can damage macromolecules and lipid
membranes [41,42]. Although the vast body of clinical ex-
perience considers systemic chemotherapy with doxo-
rubicin to be a well tolerated and effective choice for
most potentially anthracycline-sensitive tumors [43], its
cardiotoxicity combined with the risk of promoting hep-
atic dysfunction [44] can limit its clinical application.
Thus, although the use of anthracyclines is standard in
antitumor activities [38,39], in an attempt to reduce ad-
verse and increase therapeutic effects intratumoral in-
jection of doxorubicin has been used both in patients
[45,46] and rats [47] with malignant brain tumors, as
well as in rat breast tumor models [48]. As a conse-
quence, intratumoral injection of doxorubicin was also
employed in this study to make the most appropriate
comparison with the protocol for the use of the new
ZnPcS4-AN photosensitizer complex for PDT.
Considering that (1) the mononuclear inflammatory
infiltration had a predominant focal distribution only in
kidneys of two animals treated with Dox and PDT com-
bined therapies; (2) the cytoplasmic vacuolation of hepa-
tocytes was observed only in the group treated with
Dox; and (3) PDT was as effective in controlling tumor
growth as Dox, it may be stated that ZnPcS4-AN mediated-
PDT can enhance the inhibition of tumor growth while
producing reduced side effects and thus representing a very
promising strategy for tumor treatment. Due to the fact
that tumor microvasculature has a discontinuous and loose
nature, favoring its spread throughout the blood stream
[49], serum and blood cell assays can be used to evaluate
the effects of the employed treatments.
Biochemical tests are widely used for diagnosis of ani-
mal diseases [50,51], as the analyzed enzymes are gener-
ally intracellular and tissue-specific, and their profile
fluctuation in the bloodstream may reflect cellular in-
jury, increased membrane permeability or cell prolifera-
tion [51]. In combination with hemogram, which can be
used to identify anemia, inflammatory, allergic and blood
clotting disorders [52,53] biochemical tests represent im-
portant tools for pathologic analysis.
Alanine aminotransferase (ALT) is found in higher
concentrations only in the liver. Thus, increased serum
levels of this particular enzyme are used to evaluate hep-
atic lesion [54]. However, in the present study none of
the treatments employed promoted significant differ-
ences in serum ALT compared to healthy animals. This
indicates that while the cytoplasmic vacuolation of hepa-
tocytes observed in animals treated with intratumoral in-
jection of Dox could represent cytoplasmic degeneration,
this was probably a mild and circumscribed event, corrob-
orating the previous suggestion that intratumoral injection
of Dox can reduce its adverse effects while increasing its
therapeutic effects [45,46].
Elevated levels of indirect bilirubin are usually observed
in situations of increased red blood cell lysis, whereas ele-
vated levels of direct bilirubin are associated with intrahe-
patic cholestasis or extrahepatic bile duct obstruction [53].
In this context, the significant increase in indirect bilirubin
with respect to the negative control observed for the tumor
control and most of the treatments could be suggestive of
hemolysis. Results of erythrogram, platelets and AST cor-
roborate this assumption, since there is a significant reduc-
tion of red blood cells and a significant increase in platelets
and in serum AST observed for the same groups, com-
pared to healthy animals (negative control). However, ex-
cept for the ZnPc group (one of the PDT controls), which
showed HGB values below the reference values, all other
groups presented values of the erythrogram within the
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reference values, despite the significant differences ob-
served. Thus, results suggest that the tumor implantation
was responsible for most of the observed changes in bio-
chemical and blood count, including the leukogram data,
which presented both a significantly decreased number of
lymphocytes and an increased number of neutrophils +
monocytes, evidencing the immune changes caused by the
Ehrlich tumor.
Conclusion
In conclusion, ZnPcS4-AN-mediated PDT enhanced the
inhibition of tumor growth while producing practically
no adverse effects and thus emerges as a very promising
nanotechnology-based strategy for cancer treatment.
Methods
Chemicals
Doxorubicin, ketamin and xylazin were obtained as chlor-
hydrate. Lyophilized doxorubicin, sold as Doxofil 50 mg,
was obtained from Ítaca Laboratórios Ltda (Rio de Janeiro,
Brazil); ketamin, sold as Dopalen 100 mg/mL, was ob-
tained from Ceva Animal Health Ltd (São Paulo, Brazil);
and xylazin (Coopazine® 20 mg/mL) came from Coopers
(São Paulo, Brazil). Eosin methylene blue (Wright and
Giemsa formulations) and trypan blue were purchased
from Vetec Fine Chemistry Ltd (Rio de Janeiro, Brazil)
and Sigma-Aldrich Co (São Paulo, Brazil), respectively. Zn
(II) Phthalocyanine tetrasulfonate (Catalog # ZnPcS4-834)
was obtained from Frontier Scientific Inc. (Utah, USA).
Albumin nanospheres containing zinc-phthalocyanine
tetrasulfonate
The new formulation of bovine serum albumin nano-
spheres loaded with phthalocyanine (ZnPcS4-AN) was
based on previous work described by the São Paulo Uni-
versity PI# 0.803.473-7, with small changes. Briefly, the
sunflower oil and the Span-70 were obtained from Aldrich
Chemical Company, whereas bovine serum albumin was
obtained from Calbiochem. The 2-propanol, analytical
grade, was used as received. The albumin nanoparticle
used in this study was prepared according to the method
of heat denaturation using the mechanical stirring process
at high-speed from an ultra-turrax setup to optimize the
preparation of the nanoparticles. This method of prep-
aration involves the formation of protein crosslink in
suspension, with the initial formation of small drops of
aqueous solution of albumin dissolved in an immiscible
liquid phase (oily phase). The solidification of these drops
through crosslinked covalent-bonding leads to the isolation
of albumin nanoparticles. The entrapped material (in this
case the ZnPcS4 as a photosensitizer) was initially dispersed
in the albumin aqueous phase. The aqueous solutions of al-
bumin (range from 50 to 300 mg/mL) and 300 μL of a
stock solution 1.0 mM of ZnPcS4, were prepared in saline
phosphate buffer (PBS) at pH= 7.4. At the same time
100 mL of the sunflower oil (containing 5% of Span 70, v/v)
was initially added to a boiling flask of 100 mL. The
ZnPcS4/albumin initial solution was dropped into the flask
with continuous stirring using the ultra-turrax setup (5000
to 25000 rpm) for 20 minutes while the temperature of the
system was fixed at 8°C. The mixture was then emulsified
by ultrasound for some minutes at 250 W. In another boil-
ing flask 100 mL of sunflower oil (containing 3% of Span
70) was pre-heated at 100°C under continuous agitation for
30 minutes. The initial emulsion obtained as described
above was gently dropped directly onto the pre-heated sun-
flower oil in the boiling flask. After the formation of the ini-
tial emulsion the whole system was stirred at 10000 rpm
for 10 minutes at 100°C. The final suspension was then
cooled down to room temperature under continuous mag-
netic stirring. The obtained nanoparticles were washed with
ethyl ether (3 × 30 mL) for oil separation, following centri-
fugation at 10000 rpm. After washing, the pellet containing
the nanoparticles was lyophilized to remove any remaining
water trace and stored at 4°C. The albumin-based nano-
sized structure was lyophilized and the material was stored
and protected from light for a period of 3 months, without
any morphological alteration. The prepared nanosized
beads can be used for in vitro as well as for in vivo studies,
using cell lines and animal models.
Light source
A continuous low power (80 mW) diode laser (BWF light
source - Tech in) operating at 670 nm, the wavelength of
maximum optical absorption, adapted to an optical fiber,
was used to excite the solution containing ZnPcS4-AN.
Scanning electron microscopy
The external morphology of the bovine serum albumin
nanospheres loaded with phthalocyanine, ZnPcS4-AN was
examined by scanning electron microscopy after Au-
coating using LEO-440 with tungsten filament. This tech-
nique is important to evaluate not only the particle size
distribution, but also the morphology of the nanosized
particles that will be used for in vitro studies.
Fluorescence emission
The fluorescence analysis based on the emission spectra
of ZnPcS4 and ZnPcS4-AN was performed using a Fluor-
olog 3 Spex from Jobin-Ivon (USA) with excitation fixed
at 612 nm. The spectra were recorded in the range of
640 – 780 nm with excitation and emission slits fixed at
5/5 nm, respectively.
Zeta potential and particle size
Sample ZnPcS4-AN was examined in regard to the Zeta
potential and hydrodynamic diameter. The data were
recorded as a function of time up to 30 days using
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the Malvern Zetasizer Nanoseries (Malvern Instru-
ments, UK).
Ehrlich tumor
In order to test the efficacy in tumor remission of ZnPcS4-
AN mediated-PDT, combined or not with doxorubicin,
ascitic-derived Ehrlich cells were used following the pro-
cedures previously reported [35-37]. The Ehrlich ascitic
tumor, derived from a spontaneous murine mammary
adenocarcinoma, was maintained in ascitic form by pas-
sages in Swiss mice by weekly intraperitoneal transplant-
ation of 106 tumor cells. The ascitic fluid was collected by
intraperitoneal puncture using a sterile insulin syringe.
Ascitic tumor cell counts were done in a Neubauer hemo-
cytometer. The cells were found to be more than 99% vi-
able by the trypan blue dye exclusion method.
Animals and experimental design
All animal handling and procedures were carried out ac-
cording to the international practices for animal use and
care, and approved by the Animal Ethics Committee of
the Institute of Biological Sciences, University of Brasilia,
reference number 107748/2009. Female Swiss albino mice
(11–12 weeks old) weighing 29 ± 1 g were obtained from
the Multidisciplinary Center for Biological Research –
CEMIB of the University of Campinas (Campinas-SP,
Brazil). A total of 72 animals were acclimatized to labora-
tory conditions for two weeks before starting the study;
mice were housed in plastic cages (6/cage) at room
temperature (20 ± 2°C) in a 12 h light/dark cycle with
lights on at 6 a.m. and free access to food and filtered
water. After acclimatizing, animals were anesthetized by
intraperitoneal administration of ketamine (80 mg/kg) and
xylazine (10 mg/kg), both in the same syringe, in a final
dose of 0.1 mL/30 g for tumor implantation. A volume of
20 μL (2.5 × 106 viable cells) of Ehrlich ascitic tumor cell
suspension was injected subcutaneously in the middle to
lower posterior region of the ear (halfway from the bottom
to the top of the ear, spreading to the line of contact with
the head) for the solid form induction (a technical ap-
proach developed in our laboratory, unpublished data).
Forty-eight hours after implantation of tumor cells, all
mice had clinical tumor implanted on the ear. Animals
were randomly divided into nine groups (8/cage), as de-
tailed in Table 5: Negative control with no tumor implant-
ation (NC group); Tumor inoculation and no treatment
(CT group); Intratumoral injection of ZnPcS4-AN (ZnPC
group); Tumor irradiated only with light from the laser
setup (LS group); Intratumoral injection of ZnPcS4-AN
followed by light activation (PDT group); Intratumoral in-
jection of doxorubicin (Dox group); Intratumoral injection
of ZnPcS4-AN and Dox (ZnPc/Dox group); Intratumoral
injection of Dox followed by the same treatment as LS
group (Dox/LS group); Intratumoral injection of ZnPcS4-
AN and Dox followed by light activation as in PDT group
(Dox/PDT).
The energy fluence (100 J/cm2) used in this study was
previously tested in a lingual tumor model [18]. To reach
this energy density the tumor irradiation fields were stan-
dardized at 10 mm of circular diameter, the laser power
was uniform and constant at 80 mW, and the time of laser
irradiation was 16 minutes. The treatments were per-
formed once a day every three days. During the experi-
mental time, mice were clinically examined for clinical
alterations.
Procedures and measurements
Twenty-four hours after the last treatment, animals were
anesthetized with a mixture of xilazin and ketamin ac-
cording to the method described above. Blood samples
(1 mL) collected by cardiac puncture were used to carry
out hemogram and biochemical dosages of total bilirubin,
Table 5 Description of experimental groups
Group Treatment Treatment
abbreviation
Experimental design
Tumor ZnPcS4-AN Laser Doxorubicin
1 Filtered water and no tumor implantation (negative control) NC - - - -
2 Tumor inoculation and no treatment (control tumor) CT + - - -
3 Intratumoral injection of 20 μL (0.5 mM) ZnPcS4-AN ZnPc + + - -
4 Tumor irradiated only with light from a laser setup working at 670 nm,
in a total dose of 100 J/cm2
LS + - + -
5 Intratumoral injection of 0.5 mM ZnPcS4-AN followed by light
activation considering the same treatment as described for group 4
PDT + + + -
6 Intratumoral injection of 20 mg/m2 doxorubicin Dox + - - +
7 Intratumoral injection of 0.5 mM ZnPcS4-AN and 20 mg/m
2 Dox ZnPc/Dox + + - +
8 Intratumoral injection of 20 mg/m2 Dox and the same treatment
as group 4
Dox/LS + - + +
9 Intratumoral injection of 0.5 mM ZnPcS4-AN and 20 mg/m
2
Dox and the same treatment as group 5
Dox/PDT + + + +
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direct bilirubin, indirect bilirubin, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), gamma gluta-
myl transferase (GGT), alkaline phosphatase, creatinine,
and urea. Hemogram was processed in a multiple auto-
mated hematology analyzer for veterinary use, Sysmex
pocH-100iV Diff (Curitiba, Brazil) calibrated for mice in
microtubes containing EDTA as anticoagulant. Serum bio-
chemical analyses were run on the automated chemistry
analyzer ADVIA 2400 (Siemens), using the appropriate
Advia chemistry reagents and protocols. Total bilirubin,
bilirubin fractions and creatinine were measured by col-
orimetric assays; GGT by a colorimetric kinetic method;
urea by an enzymatic colorimetric method; and AST,
ALT and alkaline phosphatase by optimized kinetic
methods. Euthanasia of the animals was carried out by
cervical dislocation according to the AVMA Guidelines
on Euthanasia [55].
Tumors, liver and kidneys were surgically removed. The
width, length and thickness of tumors were measured
using a digital pachymeter, and the volume was calculated
according to Yanase et al. [56]. Afterwards, tumors and or-
gans were fixed with 10% formalin for 24 h, transferred to
70% ethanol, embedded in paraffin using an automatic tis-
sue processor (OMA® DM-40, São Paulo, Brazil), cut to 5
μm of thickness in a Leica RM2235 manual microtome
(Leica Microsystems, Nussloch, Germany) and stained with
hematoxilin-eosin (HE) for histological analyses (light mi-
croscopy). A total of five histological sections with 100 μm
distance between sections were analyzed per tumor sam-
ple. All histological sections were photographed with an
MC 80 DX camera coupled to a Zeiss Axiophot light
microscope, and tumor/necrotic areas were quantified
using Image ProPlus 5.1 software.
Statistical analysis
Statistical analysis was carried out using SPSS (Statistical
Package for the Social Sciences) version 15.0. Data were
expressed as mean ± SEM (standard error of mean) and
values of p < 0.05 were considered statistically significant.
The continuous variables were tested for normal distri-
bution with Shapiro-Wilk. For animals’ body weight, the
differences among groups were checked by ANOVA,
while differences in other variables were investigated by
ANOVA or Kruskal-Wallis test (when the data were not
normally distributed). For significant ANOVA results,
Bonferroni’s post-hoc test was chosen to carry out 2-to-
2 comparisons between the treatments. For significant
Kruskal-Wallis results, Mann–Whitney U test was per-
formed to verify differences between the treatments (2-
to-2 comparisons).
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